Advances in Nanoparticle-Based Drug Delivery Systems for Tumor-Targeted Combination Treatment

Dear Colleagues,

In this Special Issue, we will focus on recent advances in tumor-targeted combination therapy strategies based on the design of nano-drug delivery systems. The complexity and heterogeneity of tumors result in critical obstacles that severely impede treatment efficiency, such as the development of multidrug resistance, immunosuppressive tumor microenvironments and narrow therapeutic windows. Therefore, it is impossible to eliminate drug-resistant tumors and prevent cancer metastasis using a single treatment modality. Nanomedicine-mediated combination therapies provide promising approaches to synergistically potentiating the therapeutic efficacy of treatments against malignancies or to exerting superadditive (namely “1 + 1 > 2”) effects that are stronger than those of any monotherapy or their theoretical combinations. Nanotechnology-assisted cooperation among different treatments modalities including chemotherapy, chemodynamic therapy, sonotherapy, radiotherapy, phototherapy, immunotherapy and tumor metabolic reprogramming has been exploited to reverse tumor growth or even to eliminate drug-resistant cancer cells.

This Special Issue aims to publish high-quality research papers and reviews focusing on the design, synthesis, and applications of nanomedicines for tumor multimodal synergistic therapy. Both original research articles and reviews are welcome. Research areas include (but are not limited to) the following topics:

• organic/inorganic nanoparticles;
• stimuli-responsive nanomedicines;
• passive and active targeting;
• programmable drug release;
• chemotherapy;
• chemodynamic therapy;
• sonotherapy;
• radiotherapy;
• photodynamic therapy;
• photothermal therapy;
• immunotherapy;
• tumor metabolic reprogramming.

We look forward to receiving your contributions.

Prof. Dr. Zifu Li
Dr. Xiao Dong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer nanomedicine
• combination therapy
• targeted drug delivery
• stimuli-responsive
• tumor microenvironment